BioTrinity 2014 counted 130+ investment delegates from 12 countries, significantly up again on the previous year. We are delighted that corporate venture fund involvement at BioTrinity has continued to grow!  The new trend continues: a number of investor firms are sending more than one delegate, increasing the chance of you getting that all important meeting.  This year again, we actively monitor the quality of investment firms which we allow to participate, which we continue to improve year-on-year.  A significant number of Business Angels specializing in life sciences are attending, but to protect their privacy they are not automatically listed below.  This page is updated weekly or more frequently, so come back regularly to see which new investors sign up to attend.

2015 participating Investment Firms to date:

  • Abbvie (United States)
  • AbbVie Deutschland GmbH & Co. KG (Germany)
  • Abingworth LLP (UK)
  • Albion Technology & General VCT plc (UK)
  • Albion Ventures LLP (UK)
  • Angel Capital Group (incorporating London Business Angels) (UK)
  • Arthurian Life Sciences Ltd (UK)
  • Bay City Capital (Switzerland)
  • Boehringer Ingelheim GmbH (Germany)
  • BTG International Inc (United States)
  • BTG International Ltd (UK)
  • Cambridge Enterprise (UK)
  • Cambridge Innovation Capital (UK)
  • Delta Partners (Ireland)
  • Edmond de Rothschild Investment Partners (France)
  • Epidarex Capital (UK)
  • Fidelity Biosciences (UK)
  • Finance Wales (UK)
  • Forbion (Netherlands)
  • Fountain Healthcare Partners (Ireland)
  • GHO Capital Partners LLP (UK)
  • Gilde Healthcare (Netherlands)
  • Imperial Innovations (UK)
  • Index Ventures (UK)
  • Innovate UK (UK)
  • IP Group plc (UK)
  • Kurma Partners (France)
  • LSP (Netherlands)
  • Lundbeckfond Ventures (Denmark)
  • Mercia Fund Management (UK)
  • Midven (UK)
  • Mitsui & Co. Global Investment (United States)
  • MS Ventures (Netherlands)
  • MS Ventures (Switzerland)
  • NeoMed (Switzerland)
  • New Hill Management (UK)
  • Norgine Ventures (UK)
  • Novo A/S (Denmark)
  • O2h Ventures (UK)
  • Oxford Capital (UK)
  • Oxford Technology (UK)
  • QED Life Sciences (UK)
  • Seroba Kernel (Ireland)
  • Seventure Partners (France)
  • Silicon Valley Bank (UK)
  • Sofinnova (Italy)
  • SPARK Impact (UK)
  • SR One (UK)
  • SV Life Sciences (UK)
  • Takeda Ventures, Inc. (United States)
  • Ventac Partners (Spain)
  • Ysios Capital (Spain)

BioTrinity 2014 highlights
1,014 delegates from 32 countries
624 companies
184 speakers
107 company showcase presentations
2,462 one-to-one meetings
130+ investor delegates from 12 countries
61 exhibitors
86 global pharma/medtech delegates
33 corporate venture delegates